Therapeutic drug monitoring of lacosamide as add-on treatment in a neonate with therapy-resistant epilepsy due to SCN2A mutation: a case report

M. Slikkerveer, M. C. Hutten, S. Klinkenberg, A. C. S. Knijnenburg · 2026

Read Therapeutic drug monitoring of lacosamide as add-on treatment in a neonate with therapy-resistant epilepsy due to SCN2A mutation: a case report by M. Slikkerveer, M. C. Hutten, S. Klinkenberg, A. C. S. Knijnenburg (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13520411.txt.

Description

M. Slikkerveer and colleagues describe in 2026 a newborn boy with drug-resistant seizures linked to a new SCN2A gene change, treated with lacosamide under close blood-level monitoring. The seizure drug is licensed only from age two years, so newborn use is off-label and dosing guidance is absent.

Born early at 33 weeks, the infant kept seizing despite several medicines. Lacosamide was added with repeated trough level checks and heart monitoring. Reaching the target blood level needed a far higher dose than expected, split into four daily doses, with no side effects seen. The single case supports cautious, monitored use while wider studies are awaited.

Catalog record

CREATORM. Slikkerveer, M. C. Hutten, S. Klinkenberg, A. C. S. Knijnenburg
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE13249
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13520411

Browse the full library · About the Tower of Babel